Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Печать: 2151-8017
ISSN Онлайн: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015014027
pages 101-114

Alternative Scaffolds as Therapeutics in Cancer and Other Diseases

Ulrich Wuellner
Covagen AG, a Janssen Pharmaceutical Companies of Johnson & Johnson, CH-8952 Zurich-Schlieren, Switzerland
Dragan Grabulovski
Covagen AG, a Janssen Pharmaceutical Companies of Johnson & Johnson, CH-8952 Zurich-Schlieren, Switzerland

Краткое описание

Alternative scaffold proteins are a growing class of engineered binding proteins that can be identified using modern protein-engineering technologies. From large combinatorial libraries, high-quality binders can be generated essentially against any target protein of interest. Typically, these binding proteins have favorable properties in terms of size, stability, or ease of production. In this review, we focus on alternative scaffold binders for applications mainly in oncology. We highlight recent advances in the field and provide a perspective on the potentials and challenges in the drug development process of these molecules.

Ключевые слова: oncology, protein engineering, scaffold, selection